Show simple item record

dc.contributor.authorAali, Maral
dc.date.accessioned2021-09-14T13:41:35Z
dc.date.available2021-09-14T13:41:35Z
dc.date.issued2021-09-14T13:41:35Z
dc.identifier.urihttp://hdl.handle.net/10222/80809
dc.description.abstractIron is an essential element for most forms of life, as its redox-cycling capabilities enable its participation in numerous physiological reactions. However, iron levels must be tightly regulated to avoid free iron toxicity via catalysis of reactive oxygen species (ROS), which activate pro-inflammatory pathways. Iron dysregulation and excessive ROS production (oxidative stress) have been linked to dysregulated immune response and persistent infections. Two well-known examples of pathology induced by these changes are sepsis and cystic fibrosis. At the present time, there are no specific approved treatments for immune dysregulation. Additionally, antibiotic-resistant infections are becoming more difficult to clear. Iron chelators are potentially capable of addressing both needs by restricting iron availability for ROS production and reducing bacterial growth through nutritional immunity. Thus, we sought to investigate the anti-inflammatory and anti-bacterial effects of iron chelation by using DIBI, a highly specific, synthetic iron chelator. DIBI’s efficacy in vivo was assessed in three murine models of sepsis (endotoxemia, CASP, and CASP-I) and it was compared to the FDA-approved iron chelators deferiprone, deferoxamine, and desferasirox. We found that DIBI effectively alleviated sepsis-induced leukocyte-endothelial interactions and preserved capillary perfusion in the intestinal microvasculature. Moreover, when administered in combination with an antibiotic, imipenem, DIBI reduced bacterial growth and improved survival outcome. In vitro, DIBI had a dose-specific effect on the secretion of IL-6 and IL-8 by nasal epithelial cells with cystic fibrosis disease-causing mutations. The lower studied dose of DIBI (25 μM) had a pro-inflammatory effect, whereas the higher dose (200 μM) had an anti-inflammatory effect. Overall, these findings suggest a promising role for the therapeutic application of DIBI, as a novel approach for attenuating the dysregulated inflammatory response and potential adjuvant in anti-bacterial therapy.en_US
dc.language.isoenen_US
dc.subjectInflammationen_US
dc.subjectInfectionen_US
dc.subjectIronen_US
dc.subjectSepsisen_US
dc.subjectIron Chelationen_US
dc.subjectCystic Fibrosisen_US
dc.titleRole of Iron Chelation in Inflammation and Infectionen_US
dc.typeThesisen_US
dc.date.defence2020-07-17
dc.contributor.departmentDepartment of Physiology & Biophysicsen_US
dc.contributor.degreeDoctor of Philosophyen_US
dc.contributor.external-examinerDr. Lin Zouen_US
dc.contributor.graduate-coordinatorDr. Alex Quinnen_US
dc.contributor.thesis-readerDr. Zhenyu Chengen_US
dc.contributor.thesis-readerDr. David Hoskinen_US
dc.contributor.thesis-readerDr. Younes Aninien_US
dc.contributor.thesis-supervisorDr. Christian Lehmannen_US
dc.contributor.thesis-supervisorDr. Valerie Chappeen_US
dc.contributor.ethics-approvalReceiveden_US
dc.contributor.manuscriptsNot Applicableen_US
dc.contributor.copyright-releaseNot Applicableen_US
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record